ORIGINAL RESEARCH article
Front. Microbiol.
Sec. Microorganisms in Vertebrate Digestive Systems
Volume 16 - 2025 | doi: 10.3389/fmicb.2025.1647668
Clinical Features and Gut Microbiota Alterations in Hypertensive Individuals with Left Ventricular Hypertrophy
Provisionally accepted
- 1Guangxi Medical University, Nanning, China
- 2Yulin First People’s Hospital, The Sixth Affiliated Hospital of Guangxi Medical University, Yulin, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: This study aims to identify potential diagnostic biomarkers for individuals with hypertension and left ventricular hypertrophy (LVH) by characterizing associated clinical features and gut microbiota profiles. Methods: Participants were classified into three groups: a hypertrophy group (hypertension with LVH, n = 63), a non-hypertrophy group (hypertension without LVH, n = 64), and a control group (healthy participants, n = 33). Clinical parameters were recorded, and fecal samples were analyzed for microbial diversity, abundance, and distribution. Results: Patients in the hypertrophy group exhibited elevated body mass index (BMI), uric acid, triglycerides, and homocysteine levels, as well as reduced estimated glomerular filtration rate and high-density lipoprotein cholesterol. Structural cardiac changes were more pronounced in this group. Increased BMI and γ-glutamyl transferase levels emerged as independent risk factors for LVH. A significant reduction in Actinobacteria abundance was observed in the hypertrophy group compared to healthy controls. At the genus level, microbial compositions in the non-hypertrophy and control groups were more similar. Blautia was significantly enriched in patients with LVH, while Streptococcus equinus showed increased abundance at the species level (p < 0.05). The area under the receiver operating characteristic curve for gut microbiota markers in distinguishing patients with LVH from healthy controls was 0.839, and 0.796 when differentiating from patients with hypertension but without LVH. Conclusion: Patients with hypertension and LVH demonstrated distinct metabolic abnormalities and alterations in gut microbiota composition. These findings reported potential microbial biomarkers and pathways for the prevention and management of hypertension-related target organ damage.
Keywords: clinicalindicators, high-throughputsequencing, Hypertension, Gutmicrobiota, left ventricular hypertrophy
Received: 17 Jun 2025; Accepted: 25 Sep 2025.
Copyright: © 2025 Cai, Liu, Zeng, Xu, Jiang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Chun-Mei Zeng, zengchunmeizcm@126.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.